Seasoned Actors & Cysteinyl Leukotrienes: Food Anaphylaxis Guide
“`html
RSV Vaccine Approved for Older Adults: A Breakthrough in Respiratory Protection
Understanding RSV and Why It’s a Threat to Seniors
Respiratory Syncytial Virus (RSV) is a common respiratory virus that usually causes mild, cold-like symptoms. Tho, for older adults, particularly those with underlying health conditions, RSV can be severe. It’s a leading cause of pneumonia, bronchitis, and hospitalization, and contributes significantly to excess mortality during flu season. Prior to the development of vaccines, RSV was estimated to cause between 60,000 and 160,000 hospitalizations and 6,000 to 10,000 deaths annually among adults 65 years and older in the United States.
The vulnerability of older adults stems from age-related decline in immune function (immunosenescence) and the increased prevalence of chronic conditions like heart failure and chronic obstructive pulmonary disease (COPD). These factors make it harder for the body to fight off RSV infection, leading to more severe outcomes.
The Arexvy Vaccine: How it effectively works and Trial Results
Arexvy, developed by GSK, is a recombinant subunit vaccine containing a stabilized prefusion F protein. This protein is found on the surface of the RSV virus and is crucial for the virus to enter cells. By presenting this protein to the immune system, the vaccine triggers the production of antibodies that can neutralize the virus and prevent infection.
The Phase 3 PROTECT trial,published in the New England Journal of Medicine on November 20,2025,involved over 20,000 adults aged 60 years and older.The trial demonstrated a vaccine efficacy of 82.6% against RSV-associated lower respiratory tract disease (LRTD) – defined as having at least two symptoms including cough, shortness of breath, wheezing, or fever. Efficacy against severe LRTD, requiring hospitalization, was 94.1%.
Importantly, the trial also assessed safety. The most common side effects reported were local reactions at the injection site (pain, redness, swelling) and systemic symptoms like fatigue, muscle aches, and headache. serious adverse events were rare and not definitively linked to the vaccine.
| Outcome | Vaccine Group (n=10,048) | placebo Group (n=10,048) | Vaccine Efficacy (%) |
|---|---|---|---|
| RSV-associated LRTD | 68 | 123 | 82.6 |
| Severe RSV-associated LRTD (hospitalization) | 6 | 37 | 94.1 |
Who Should Get the RSV Vaccine?
The FDA approved Arexvy for adults aged 60 years and older. The Centers for disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) will provide further recommendations on who should *routinely* receive the vaccine. Currently, the CDC recommends that adults aged 60 years and older may receive a dose of RSV vaccine, based on shared clinical decision